Main Directory
Articles 2591
CME 2
eCommerce 0
Medical Web Sites Directory 93
Podcasts 94
Web Design and Hosting 2




Rituximab Phase 2/3 Trial Fails to Meet Primary End Point in Primary Progressive MS
Link ID 4920
Title Rituximab Phase 2/3 Trial Fails to Meet Primary End Point in Primary Progressive MS
Url http://www.medscape.com/viewarticle/573131?src=rss
Description Genentech and Biogen Idec announced top-line results from a phase 2/3 trial in primary progressive multiple sclerosis, showing that treatment with rituximab did not meet the primary end point of time to confirmed disease progression over 96 weeks. Medscape Medical News
Category Articles > Allergy and Clinical Immunology
Keywords
Date Apr 17, 2008
Contact Name
Email
Write a Review   Add to My Favorite   Refer it to Friend   Report Broken Link  

Average Visitor Rating: 0.00 (out of 5)
Number of ratings: 0 Votes
Visitor Rating

 Other links at Articles > Allergy and Clinical Immunology
1. Announcing the Otolaryngology-Head and Neck Surgery Section of The Medscape Journal of Medicine
  David Goldenberg, MD, Division of Otolaryngology-Head and Neck Surgery, The Pennsylvania State University, The Milton S. Hershey Medical Center, announces this new section of The Medscape Journal.
The Medscape Journal of Medicine
Category:   Articles > Allergy and Clinical Immunology


2. AIDS 2008: HIV Basic Science and Pathogenesis
  Dr. Mario Stevenson reviews new data on viral and host factors involved in HIV pathogenesis, presented at AIDS 2008: XVII International AIDS Conference, August 3-8, 2008, in Mexico City, Mexico. Medscape HIV/AIDS
Category:   Articles > Allergy and Clinical Immunology


3. FDA Approvals: Asmanex Twisthaler, Accretropin, Mycamine
  The FDA has approved an expanded indication for mometasone furoate inhalation powder (Asmanex Twisthaler), somatropin (recombinant) injection (Accretropin), and micafungin infusion (Mycamine). Medscape Medical News
Category:   Articles > Allergy and Clinical Immunology


4. Three-Dose IM Anthrax Vaccination Provides Effective Immune Priming
  Anthrax vaccine administered in three doses by intramuscular (IM) injection provides noninferior immunological priming and reduces injection site reactions when compared with the licensed schedule of four doses administered subcutaneously (SC), an interim analysis of a phase IV clinical trial indicates. Reuters Health Information
Category:   Articles > Allergy and Clinical Immunology


5. Castle Connolly "Top Doctors" Ratings
  John Connolly, EdD, President and CEO of Castle Connolly, New York, NY, explains how to find "the best doctors."
The Medscape Journal of Medicine
Category:   Articles > Allergy and Clinical Immunology




Home      New Listings      Hot Listings      Top Rated      Editor Pick      Add a Listing      Update a Listing      Get Rated      Upgrade a Listing
Valid XHTML 1.0 Transitional   Valid CSS